Precision Medicine For Your Practice: Prenatal Cell-Free DNA Screening

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships.

If applicable, all relevant financial relationships have been mitigated.

Credit Renewal Dates: August 22, 2019, August 21, 2022

Disclosure Statement: In order to assure the highest quality of certified CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty, planners and members of the AMA CME Program Committee disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. The following disclosures are provided:

• Siobhan Dolan, MD, MPH, Stockholder of Sequenom

• Jeanette McCarthy, PhD, MPH, Consultant to Big Science Media, Omicia, and Precision Medicine Advisors

• Colleen Schmitt, MS, CGC, Employee of Counsyl, Inc.

• Suzanna Schott, ScM, CGC, Stockholder of Merck, Amgen, and Teva

• Janet K. Williams, PhD, RN, FAAN, Stockholder of Pfizer

No other planners or faculty have relevant financial relationships to disclose.